Table 1.
Baseline patient characteristics of patients in the GI involvement and non-GI involvement groups
| Characteristic | GI involvement group | Non-GI involvement group | p value | |
|---|---|---|---|---|
| n(%) | n(%) | |||
|
| ||||
| Age, years | Median (Range) | 65 (25–79) | 64 (19–78) | |
| Gender | Male | 15 (62.5) | 62 (58.5) | 0.82 |
| Female | 9 (37.5) | 44 (41.5) | ||
| Performance status by ECOG | 0–1 | 16 (69.6)* | 84 (79.2) | 0.40 |
| ≥2 | 7 (30.4)* | 22 (20.8) | ||
| Disease type | DLBCL | 20 (83.3) | 74 (69.8) | 0.21 |
| TFL | 3 (12.5) | 28 (26.4) | ||
| PMBCL | 1 (4.2) | 4 (3.8) | ||
| Double or triple hit | 5 (29.4)* | 18 (24.7)* | 0.76 | |
| Ann Arbor Stage** | I/II | 4 (16.7) | 22 (20.8) | 0.78 |
| III/IV | 20 (83.3) | 84 (79.2) | ||
| IPI score** | 0–2 | 3 (13) * | 36 (34) | 0.08 |
| 3–5 | 20 (87)* | 70 (66) | ||
| Cell of origin | GCB-like | 14 (58.3) | 60 (56.6) | 0.99 |
| Non-GCB | 6 (25) | 27 (25.5) | ||
| Unknown | 4 (16.7) | 19 (17.9) | ||
| Product | Axi-cel | 1 (4.2) | 10 (9.4) | 0.69 |
| Tisa-cel | 23 (95.8) | 96 (90.6) | ||
*
Percentages based on number of patients with available data.
**
At the time of leukapheresis
ECOG, Eastern Cooperative Group performance status grade; DLBCL, diffuse large B cell lymphoma; TFL, transformed follicular lymphoma; GCB, germinal center B, axi-cel, axicabtagene ciloleucel, tisa-cel, tisagenlecleucel